Bank of Commerce is a bank holding company. Through its subsidiary, the company provides a range of financial services and products for business and retail customers. The services the company provides include those offered by banks of similar size and character in California. The company's principal deposit products include the following types of accounts; checking, interest-bearing checking, money market, savings and certificates of deposit. The company also provides sweep arrangements, commercial loans, construction loans, term loans, consumer loans, safe deposit boxes, and electronic banking services. The company does not provide trust services or international banking services.

Crimson Wine Group is engaged in the business of producing and selling wines. Through its wholly-owned subsidiaries, the company owns seven wineries: Pine Ridge Vineyards, Archery Summit, Chamisal Vineyards, Seghesio Family Vineyards, Double Canyon, Seven Hills Winery and Malene Wines. The company has two operating segments, Wholesale net sales and Direct to Consumer net sales. Wholesale net sales include all sales through a third party where prices are given at a wholesale rate, whereas Direct to Consumer net sales include retail sales in the tasting room, remote sites and on-site events, wine club net sales and other sales made directly to the consumer without the use of an intermediary.

Golub Capital BDC is registered as an externally managed, closed-end, non-diversified management investment company. The company makes investments primarily in one stop (a loan that combines characteristics of first lien senior secured loans and second lien or subordinated loans) and other senior secured loans of middle-market companies that are, in most cases, sponsored by private equity firms. The company's investment objective is to generate existing income and capital appreciation by investing primarily in one stop and other senior secured loans of United States middle-market companies.

Kodiak Sciences is a clinical stage biopharmaceutical company focusing on therapeutics to treat chronic, high-prevalence retinal diseases. The company's main product candidate is KSI-301, a biologic therapy built with the company's antibody biopolymer conjugate platform, which is designed to maintain drug levels in ocular tissues. KSI-301 is used to treat patients with wet age-related macular degeneration, diabetic retinopathy, including diabetic macular edema, and macular edema due to retinal vein occlusion. The company has applied its antibody biopolymer conjugate platform to develop additional product candidates beyond KSI-301, including KSI-501, its bispecific anti-IL-6/VEGF bioconjugate.

Live Oak Bancshares is a bank holding company. Through its subsidiary, Live Oak Banking Company (the Bank), the company is engaged in providing lending and deposit related services. The company directly or indirectly holds the following wholly-owned subsidiaries: Canapi Advisors, LLC, which provides investment advisory services; Live Oak Ventures, Inc., which invests in businesses that align with the company's initiative in financial technology; Live Oak Grove, LLC, which provides an on-site restaurant location; Government Loan Solutions, Inc., which is a management and technology consulting firm; and 504 Fund Advisors, LLC, which serves as the investment advisor to the 504 Fund, a closed-end mutual fund.

Party City Holdco is a holding company. Through its subsidiaries, the company is a supplier of decorated party goods. The company has two segments: Retail, which operates retail party supply stores in the U.S. and Canada, principally under the names Party City and Halloween City, and it operates e-commerce websites, principally through the domain name PartyCity.com; and Wholesale, which designs, manufactures, contracts for manufacture and distributes party goods, including paper and plastic tableware, metallic and latex balloons, Halloween and other costumes, accessories, novelties and stationery throughout the world.

Penns Woods Bancorp is a bank holding company. Through its subsidiaries, Jersey Shore State Bank (JSSB) and Luzerne Bank (collectively, the Banks), the company is engaged in commercial and retail banking which includes the acceptance of time, savings, and demand deposits, the funding of commercial, consumer, and mortgage loans, and safe deposit services. The Banks provide insurance, securities brokerage services, annuity and mutual fund investment products, and financial planning through JSSB's subsidiary, The M Group, Inc. Services provided by the Banks include accepting time, demand and savings deposits including Super NOW accounts, money market accounts, and fixed rate certificates of deposit.

Provention Bio is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. The company's principal product candidates include: PRV-031 (teplizumab, anti-CD3 mAb) for the interception of type 1 diabetes; PRV-015 (anti-IL-15 mAb) for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 (oral CSF-1R inhibitor) for the treatment of Crohn's disease; PRV-300 (anti-TLR3 mAb) for the treatment of ulcerative colitis; and PRV-3279 (humanized anti-CD32B and CD79B bispecific) for the treatment of lupus.

Spok Holdings provides a suite of unified clinical communication and collaboration solutions that include call center operations, clinical alerting and notifications, one-way and two-way wireless messaging services, mobile communications and public safety solutions. The company also develops, sells and supports enterprise-wide systems for hospitals and other organizations needing to automate, centralize and standardize mission clinical communications. These solutions are used for contact centers, clinical alerting and notification, mobile communications and messaging and for public safety notifications.

Tenax Therapeutics is a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases. Through its wholly owned subsidiary, Life Newco, Inc. (Life Newco), the company owns a license granting Life Newco a right to develop and commercialize pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion / 5ml vial in the United States and Canada. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure.

Verrica Pharmaceuticals is a dermatology therapeutics company focused on the development and commercialization of treatments for people living with skin diseases. The company's primary product candidate, VP-102, is a proprietary drug-device combination of its topical solution of cantharidin, a naturally sourced agent to treat topical dermatological conditions, administered through its single-use precision applicator. The company is initially developing VP-102 for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts. In addition, the company is also developing VP-102 for the treatment of external genital warts.

Xerox is a workplace technology company. The company's business areas are: Xerox Services, which offerings in this area are Intelligent Workplace Services and a range of Digital Services that utilize the company's software capabilities in Workflow Automation, Personalization and Communication Software, Content Management Solutions, and Digitization Services; Workplace Solutions, which is made up of two product groups, Entry and Mid-Range, which share common technology, manufacturing and product platforms; and Graphic Communications and Production Solutions, which are designed for customers in the graphic communications, in-plant and production print environments with high-volume printing requirements